Greg Pyszczymuka
Corporate Officer/Principal presso AYTU BIOPHARMA, INC.
Patrimonio netto: 64 661 $ in data 30/04/2024
Profilo
Greg Pyszczymuka is currently working as the Vice President-Commercial at Neos Therapeutics, Inc. since 2020.
He is also currently serving as the Chief Commercial Officer at Aytu Biopharma, Inc. In terms of education, Mr. Pyszczymuka holds an MBA from Argosy University and an undergraduate degree from Rutgers State University of New Jersey.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
AYTU BIOPHARMA, INC.
0.41% | 31/03/2024 | 22 768 ( 0.41% ) | 64 661 $ | 30/04/2024 |
Posizioni attive di Greg Pyszczymuka
| Società | Posizione | Inizio |
|---|---|---|
| AYTU BIOPHARMA, INC. | Corporate Officer/Principal | - |
| NEOS THERAPEUTICS, INC. | Corporate Officer/Principal | 01/11/2018 |
Formazione di Greg Pyszczymuka
| Rutgers State University of New Jersey | Undergraduate Degree |
| Argosy University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| AYTU BIOPHARMA, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Neos Therapeutics, Inc.
 Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |
- Borsa valori
- Insiders
- Greg Pyszczymuka
